Gingival RecessionNCT03734458
Platelet Rich Fibrin and Autologous Fibrin Glue
A study testing Group A - PRF plus AFG with a CAF, Group B - PRF only with a CAF and Group C - CTG with a CAF in people with Gingival Recession, run by University of California, San Francisco at 1 site in United States.
Trial summary
Platelet-rich fibrin (PRF) and Autologous Fibrin Glue (AFG) are fibrin preparation derived from human blood samples and are used in regenerative dentistry. Aim: The aim of this study is to evaluate the level of root coverage using PRF (+) AFG with a coronally advanced flap (CAF) or PRF only with a CAF compared to a… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Gingival Recession
- What is being tested?
- Group A - PRF plus AFG with a CAF, Group B - PRF only with a CAF and Group C - CTG with a CAF
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2019to Jan 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women aged 18 years or over
- Miller's Class 1 and Class 2 recession
- Localized gingival recession of 1-6mm present on 1 or 2 continuous single rooted teeth. Gingival recession is measured from the cemental-enamel junction (CEJ; a stable anatomical landmark on every tooth) to the gingival margin.
Who cannot join
- Current tobacco use (greater than 1 cigarette/week) or history of quitting < 5 years previously (self reported)
- Poor oral hygiene (plaque index of 2 or greater) or active periodontal disease (diagnosis of moderate chronic periodontal disease or greater)
- Currently taking aspirin, prescription blood thinners
- Type II diabetes with HbA1c greater than 7
- Immunosuppressed or any other systemic condition that would disqualify subject as an acceptable surgical candidate
Trial locations and contacts
1 site in 1 country.
United States1 site
UCSF School of Dentistry
San Francisco, California, 94143
About this study
Official title: Platelet Rich Fibrin and Autologous Fibrin Glue for Treating Periodontal Recession Defects: a Comparative Clinical Study
Platelet-rich fibrin (PRF) and Autologous Fibrin Glue (AFG) are fibrin preparation derived from human blood samples and are used in regenerative dentistry.
Aim: The aim of this study is to evaluate the level of root coverage using PRF (+) AFG with a coronally advanced flap (CAF) or PRF only with a CAF compared to a sub-epithelial connective tissue graft (CTG) with a CAF for treating Class 1 and 2 gingival recession defects. Additionally, to evaluate the level of keratinized tissue tissue thickness and width using PRF (+) AFG with a CAF or PRF only with a CAF compared to CTG with CAF for Class 1 and 2 gingival recession defects.
Method: 48 patients with recession defects will be randomly divided into three different treatment groups. Treatment Group A (n=16) will consist of patients treated with PRF (+) AFG with a CAF, Group B (n=16) will consist of patients treated with PRF only with a CAF and Group C (n=16) will consits of patients treated with CTG with CAF as a control. Clinical measurements will be assessed at baseline and at 1 month and 6 months after the surgery. The clinical measurements that will be recorded, include probing depth, clinical attachment level, and gingval recession parameters. The gingival recession parameters include recession width, depth and thickness.
Read the detailed description
Specific aim 1: Evaluate the level of root coverage using Platelet Rich Fibrin (PRF) plus Autologous Fibrin Glue (AFG) with a coronally advanced flap (CAF) or PRF only with a CAF compared to subepithelial connective tissue graft (CTG) with a CAF for Class 1 and 2 gingival recession defects.
Specific aim 2: Evaluate the level of keratinized tissue thickness and width using PRF plus AFG with a CAF, PRF only with a CAF or a SCTG with CAF for Class 1 and 2 gingival recession defects.
Research design and methods:
Subjects and treating clinician will not be aware of the treatment arm until immediately before the surgery. Each treatment arm will use the same surgical protocol for treating gingival recession and will differ by the material used to cover the tooth root. Intervention A will use PRF with the addition of AFG. Intervention B will use PRF. The control arm will use CTG.
Methods: A total of 48 patients with recession defects will be randomly assigned to three different treatment groups. Treatment group A (n=16) will consist of patients treated with PRF plus AFG with a CAF, Group B (n=16) will consist of patients treated with PRF with a CAF and Group C (n=16) will consist of patients treated with CTG with a CAF. Group C will be the control group. Clinical measurements, including recession defect length and gingival width and thickness, will be evaluated at baseline, one month and six months after treatment. For standardization, measurements will be taken using pre- fabricated stents with an endo file stopper. A visual analogue scale will be used to compare post-operative pain between the two procedures.
Study Subjects Overview: This study will use the patient pool of the periodontal clinic at the UCSF Dental Center to identify potentially eligible patients. The periodontal clinic regularly receives a high volume of referred patients for treatment of gingival recession.
Inclusion Criteria:
- Men and women aged 18 years or over 2. Miller's Class 1 and Class 2 recession Miller's Class 1 - Marginal tissue recession which does not extend to the mucogingival junction. There is no periodontal loss (bone or softi tssue ) in the interdental area, and 100% root coverage can be anticipated.
Miller's Class 2 - Marginal tissue recession which extends beyond the mucogingival junction.There is no periodontal loss (bone or softi tssue ) in the interdental area, and 100% root coverage can be anticipated.
5 Localized gingival recession of 1-6mm present on 1 or 2 continuous single rooted teeth. Gingival recession is measured from the cemental-enamel junction (CEJ; a stable anatomical landmark on every tooth) to the gingival margin.
Exclusion Criteria:
- Current tobacco use (greater than 1 cigarette/week) or history of quitting < 5 years previously (self reported)
- Poor oral hygiene (plaque index of 2 or greater) or active periodontal disease (diagnosis of moderate chronic periodontal disease or greater)
- Currently taking aspirin, prescription blood thinners, or present with any coagulopathies 4. Type II diabetes with HbA1c greater than 7
- Immunosuppressed or any other systemic condition that would disqualify subject as an acceptable surgical candidate Retention strategy: In the course of review if funding becomes available modest financial incentives will be made to patients returning for the 1 month and 6 month recall appointments. Otherwise, telephone and email reminders will be made by study staff for recall appointments.
PRF Preparation The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
Sup-epithelial connective tissue harvest:
The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
Surgical procedure:
An acrylic stent will be made using patient's models/dental cast. On the day of the procedure, the recession defect length and width will be measured using the pre-fabricated stent and periodontal probe. The gingival thickness will be evaluated using an endo reamer and stopper. For all groups, the recipient bed will be prepared using a horizontal sulcular incision. A split thickness flap will be reflected to expose the periosteum. The flap will be extended mesio-distally from the recession defect for adequate blood supply and for passive primary closure. For Group C - CTG w/ CAF, the CTG harvested from the palate will be placed over the recession defect. For Group B PRF w/CAF, the PRF membrane will be placed on the recession defect. For Group A -PRF plus AFG w/ CAF, the AFG liquid will be applied over the exposed roots of the recession defect and the PRF membrane will be placed on the recession defect. For all groups, the recipient flap will cover the graft and be coronally positioned over the cemento-enamel junction. The recipient site will be sutured using a sling suturing technique with 5-0 vicryl sutures. Care will be taken to achieve tension free primary closure for all the groups. Hemostasis will be achieved by applying gentle finger pressure for up to 5 minutes.
Data collection and Analysis:
Clinical measurements will be assessed at baseline and at 1 month and 6 months after surgery. The clinical measurements will be recorded using a pre- fabricated stent and periodontal probe. The clinical measurements that will be recorded, include probing depth, clinical attachment level, and gingival recession parameters. The gingival recession parameters include recession width, depth and thickness. Presence of plaque and gingival inflammation will also be recorded using Loe \& Silness Plaque and Gingival Index.
Standard clinical care:
- Each subject receives regular care for the root coverage procedure.
In brief, the regular care involves the following:
- Root coverage procedure involves coverage of the exposed root to improve esthetics, decrease caries risk and increase keratinized tissue. There are several techniques supported in the literature including the techniques used for treatment arm (Group B and Group C) of the study described below.
Study Procedures - After successful enrollment and randomization into a given treatment arm, subject are treated according to normal clinical care for the treating the soft tissue recession. Particpant's study models are taken and stent is created using the model.
The following study interventions are performed during the regular care phase:
Baseline measurement- The clinical measurements will be taken non-invasively using a pre- fabricated stent, periodontal probe and endo reamer with stopper before the surgery (baseline) and at 1 month, 6 months post surgery.
- Measurements will be recorded by the study coordinator on a coded data collection sheet. Soft tissue recession treatment groups : Group A - PRF plus AFG with a CAF - The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
Group B - PRF only with a CAF - The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
Group C - CTG with a CAF (Control) - Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
Surgical procedure:
An acrylic stent will be made using patient's models/dental cast. On the day of the procedure, the recession defect length and width will be measured using the pre-fabricated stent and periodontal probe. The gingival thickness will be evaluated using an endo reamer and stopper. For all groups, the recipient bed will be prepared using a horizontal sulcular incision. A split thickness flap will be reflected to expose the periosteum. The flap will be extended mesio-distally from the recession defect for adequate blood supply and for passive primary closure. For Group C - CTG w/ CAF, the CTG harvested from the palate will be placed over the recession defect as described above. For Group B PRF w/CAF, the PRF membrane will be placed on the recession defect. For Group A -PRF plus AFG w/ CAF, the AFG liquid will be applied over the exposed roots of the recession defect and the PRF membrane will be placed on the recession defect. For all groups, the recipient flap will cover the graft and be coronally positioned over the cemento-enamel junction. The recipient site will be sutured using a sling suturing technique with 5-0 vicryl sutures. Care will be taken to achieve tension free primary closure for all the groups. Hemostasis will be achieved by applying gentle finger pressure for up to 5 minutes.
Post operative visit (Week 1): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient.
Post operative visit (Week 2): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient.
Post operative visit (1 months): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient. Topical local anesthetic will be applied on the treated area and the clinical measurements will be taken non-invasively using the pre-fabricated stent, periodontal probe and endo reamer with stopper at one month post surgery.
Post operative visit (6months): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient. Clinical measurements are repeated as described above.
- Conditions
- Gingival Recession
- Being tested
- Group A - PRF plus AFG with a CAF, Group B - PRF only with a CAF, Group C - CTG with a CAF
- Medical subject headings
- Gingival Recession
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group A - PRF plus AFG with a CAFOther
Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
Group B - PRF only with a CAFOther
Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
Group C - CTG with a CAFOther
Group C - CTG with a CAF will be used surgically to cover the exposed roots.
| Study group | Role | What they receive |
|---|---|---|
| Group A - PRF plus AFG with a CAF | Experimental | Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe. Receives: Other: Group A - PRF plus AFG with a CAF |
| Group B - PRF only with a CAF | Experimental | Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. Receives: Other: Group B - PRF only with a CAF |
| Group C - CTG with a CAF | Active comparator | Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique. Receives: Other: Group C - CTG with a CAF |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the level of root coverage using PRF plus AFG with a coronally advanced flap or PRF only with a CAF compared to subepithelial connective tissue graft with a CAF for Class 1 and 2 gingival recession defects.
To evaluate the level of root coverage using PRF plus AFG compared to CTG or PRF only compared to CTG
Measured: Baseline to 6 months
Secondary outcomes (1)
Evaluate the level of keratinized tissue thickness and width using PRF plus AFG with a CAF, PRF only with a CAF or a SCTG with CAF for Class 1 and 2 gingival recession defects.
To evaluate the level of keratinized tissue thickness and width using PRF plus AFG compared to CTG or PRF only compared to CTG
Measured: Baseline to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2018
- Study startJul 2019 (estimated)
- Primary completionJan 2021 (estimated)
- Study completionJan 2021 (estimated)
Why it stopped: IND application did not get approved
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Gingival RecessionStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yogalakshmi Rajendran, BDS MS, Principal investigator, UCSF School of Dentistry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03734458
- Sponsor's protocol ID
- 17-24111 PRF+AFG
- Status last verified
- Oct 2019
- First submitted
- 3 Oct 2018
- Last updated
- 8 Oct 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018 Feb;44(1):87-95. doi: 10.1007/s00068-017-0767-9. Epub 2017 Mar 10.
PubMed 28283682Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, Fujioka-Kobayashi M, Bishara M, Zhang Y, Wang HL, Chandad F, Nacopoulos C, Simonpieri A, Aalam AA, Felice P, Sammartino G, Ghanaati S, Hernandez MA, Choukroun J. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Investig. 2017 Jul;21(6):1913-1927. doi: 10.1007/s00784-017-2133-z. Epub 2017 May 27.
PubMed 28551729Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009 Feb;27(1):63-9. doi: 10.1080/08977190802636713.
PubMed 19089687Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barbe G, Del Corso M, Inchingolo F, Sammartino G. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012 Jun;13(7):1145-52. doi: 10.2174/138920112800624382.
PubMed 21740377Oncu E. The Use of Platelet-Rich Fibrin Versus Subepithelial Connective Tissue Graft in Treatment of Multiple Gingival Recessions: A Randomized Clinical Trial. Int J Periodontics Restorative Dent. 2017 Mar/Apr;37(2):265-271. doi: 10.11607/prd.2741.
PubMed 28196169Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e45-50. doi: 10.1016/j.tripleo.2005.07.009. Epub 2006 Jan 10.
PubMed 16504850Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e51-5. doi: 10.1016/j.tripleo.2005.07.010.
PubMed 16504851Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e37-44. doi: 10.1016/j.tripleo.2005.07.008. Epub 2006 Jan 19.
PubMed 16504849Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e56-60. doi: 10.1016/j.tripleo.2005.07.011.
PubMed 16504852Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):299-303. doi: 10.1016/j.tripleo.2005.07.012.
PubMed 16504861
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Platelet Rich Fibrin and Autologous Fibrin Glue for Treating Periodontal Recession Defects: a Comparative Clinical Study
- ClinicalTrials.gov ID
- NCT03734458
- Acronym / sponsor ID
- 17-24111 PRF+AFG
- Conditions
- Gingival Recession
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: IND application did not get approved
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- Jul 2019 (estimated)
- Primary completion
- Jan 2021 (estimated)
- Study completion
- Jan 2021 (estimated)
- First posted
- 8 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Platelet-rich fibrin (PRF) and Autologous Fibrin Glue (AFG) are fibrin preparation derived from human blood samples and are used in regenerative dentistry.
Aim: The aim of this study is to evaluate the level of root coverage using PRF (+) AFG with a coronally advanced flap (CAF) or PRF only with a CAF compared to a sub-epithelial connective tissue graft (CTG) with a CAF for treating Class 1 and 2 gingival recession defects. Additionally, to evaluate the level of keratinized tissue tissue thickness and width using PRF (+) AFG with a CAF or PRF only with a CAF compared to CTG with CAF for Class 1 and 2 gingival recession defects.
Method: 48 patients with recession defects will be randomly divided into three different treatment groups. Treatment Group A (n=16) will consist of patients treated with PRF (+) AFG with a CAF, Group B (n=16) will consist of patients treated with PRF only with a CAF and Group C (n=16) will consits of patients treated with CTG with CAF as a control. Clinical measurements will be assessed at baseline and at 1 month and 6 months after the surgery. The clinical measurements that will be recorded, include probing depth, clinical attachment level, and gingval recession parameters. The gingival recession parameters include recession width, depth and thickness.
Detailed description
Specific aim 1: Evaluate the level of root coverage using Platelet Rich Fibrin (PRF) plus Autologous Fibrin Glue (AFG) with a coronally advanced flap (CAF) or PRF only with a CAF compared to subepithelial connective tissue graft (CTG) with a CAF for Class 1 and 2 gingival recession defects.
Specific aim 2: Evaluate the level of keratinized tissue thickness and width using PRF plus AFG with a CAF, PRF only with a CAF or a SCTG with CAF for Class 1 and 2 gingival recession defects.
Research design and methods:
Subjects and treating clinician will not be aware of the treatment arm until immediately before the surgery. Each treatment arm will use the same surgical protocol for treating gingival recession and will differ by the material used to cover the tooth root. Intervention A will use PRF with the addition of AFG. Intervention B will use PRF. The control arm will use CTG.
Methods: A total of 48 patients with recession defects will be randomly assigned to three different treatment groups. Treatment group A (n=16) will consist of patients treated with PRF plus AFG with a CAF, Group B (n=16) will consist of patients treated with PRF with a CAF and Group C (n=16) will consist of patients treated with CTG with a CAF. Group C will be the control group. Clinical measurements, including recession defect length and gingival width and thickness, will be evaluated at baseline, one month and six months after treatment. For standardization, measurements will be taken using pre- fabricated stents with an endo file stopper. A visual analogue scale will be used to compare post-operative pain between the two procedures.
Study Subjects Overview: This study will use the patient pool of the periodontal clinic at the UCSF Dental Center to identify potentially eligible patients. The periodontal clinic regularly receives a high volume of referred patients for treatment of gingival recession.
Inclusion Criteria:
- Men and women aged 18 years or over 2. Miller's Class 1 and Class 2 recession Miller's Class 1 - Marginal tissue recession which does not extend to the mucogingival junction. There is no periodontal loss (bone or softi tssue ) in the interdental area, and 100% root coverage can be anticipated.
Miller's Class 2 - Marginal tissue recession which extends beyond the mucogingival junction.There is no periodontal loss (bone or softi tssue ) in the interdental area, and 100% root coverage can be anticipated.
5 Localized gingival recession of 1-6mm present on 1 or 2 continuous single rooted teeth. Gingival recession is measured from the cemental-enamel junction (CEJ; a stable anatomical landmark on every tooth) to the gingival margin.
Exclusion Criteria:
- Current tobacco use (greater than 1 cigarette/week) or history of quitting < 5 years previously (self reported)
- Poor oral hygiene (plaque index of 2 or greater) or active periodontal disease (diagnosis of moderate chronic periodontal disease or greater)
- Currently taking aspirin, prescription blood thinners, or present with any coagulopathies 4. Type II diabetes with HbA1c greater than 7
- Immunosuppressed or any other systemic condition that would disqualify subject as an acceptable surgical candidate Retention strategy: In the course of review if funding becomes available modest financial incentives will be made to patients returning for the 1 month and 6 month recall appointments. Otherwise, telephone and email reminders will be made by study staff for recall appointments.
PRF Preparation The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
Sup-epithelial connective tissue harvest:
The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
Surgical procedure:
An acrylic stent will be made using patient's models/dental cast. On the day of the procedure, the recession defect length and width will be measured using the pre-fabricated stent and periodontal probe. The gingival thickness will be evaluated using an endo reamer and stopper. For all groups, the recipient bed will be prepared using a horizontal sulcular incision. A split thickness flap will be reflected to expose the periosteum. The flap will be extended mesio-distally from the recession defect for adequate blood supply and for passive primary closure. For Group C - CTG w/ CAF, the CTG harvested from the palate will be placed over the recession defect. For Group B PRF w/CAF, the PRF membrane will be placed on the recession defect. For Group A -PRF plus AFG w/ CAF, the AFG liquid will be applied over the exposed roots of the recession defect and the PRF membrane will be placed on the recession defect. For all groups, the recipient flap will cover the graft and be coronally positioned over the cemento-enamel junction. The recipient site will be sutured using a sling suturing technique with 5-0 vicryl sutures. Care will be taken to achieve tension free primary closure for all the groups. Hemostasis will be achieved by applying gentle finger pressure for up to 5 minutes.
Data collection and Analysis:
Clinical measurements will be assessed at baseline and at 1 month and 6 months after surgery. The clinical measurements will be recorded using a pre- fabricated stent and periodontal probe. The clinical measurements that will be recorded, include probing depth, clinical attachment level, and gingival recession parameters. The gingival recession parameters include recession width, depth and thickness. Presence of plaque and gingival inflammation will also be recorded using Loe \& Silness Plaque and Gingival Index.
Standard clinical care:
- Each subject receives regular care for the root coverage procedure.
In brief, the regular care involves the following:
- Root coverage procedure involves coverage of the exposed root to improve esthetics, decrease caries risk and increase keratinized tissue. There are several techniques supported in the literature including the techniques used for treatment arm (Group B and Group C) of the study described below.
Study Procedures - After successful enrollment and randomization into a given treatment arm, subject are treated according to normal clinical care for the treating the soft tissue recession. Particpant's study models are taken and stent is created using the model.
The following study interventions are performed during the regular care phase:
Baseline measurement- The clinical measurements will be taken non-invasively using a pre- fabricated stent, periodontal probe and endo reamer with stopper before the surgery (baseline) and at 1 month, 6 months post surgery.
- Measurements will be recorded by the study coordinator on a coded data collection sheet. Soft tissue recession treatment groups : Group A - PRF plus AFG with a CAF - The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
Group B - PRF only with a CAF - The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using two 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
Group C - CTG with a CAF (Control) - Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
Surgical procedure:
An acrylic stent will be made using patient's models/dental cast. On the day of the procedure, the recession defect length and width will be measured using the pre-fabricated stent and periodontal probe. The gingival thickness will be evaluated using an endo reamer and stopper. For all groups, the recipient bed will be prepared using a horizontal sulcular incision. A split thickness flap will be reflected to expose the periosteum. The flap will be extended mesio-distally from the recession defect for adequate blood supply and for passive primary closure. For Group C - CTG w/ CAF, the CTG harvested from the palate will be placed over the recession defect as described above. For Group B PRF w/CAF, the PRF membrane will be placed on the recession defect. For Group A -PRF plus AFG w/ CAF, the AFG liquid will be applied over the exposed roots of the recession defect and the PRF membrane will be placed on the recession defect. For all groups, the recipient flap will cover the graft and be coronally positioned over the cemento-enamel junction. The recipient site will be sutured using a sling suturing technique with 5-0 vicryl sutures. Care will be taken to achieve tension free primary closure for all the groups. Hemostasis will be achieved by applying gentle finger pressure for up to 5 minutes.
Post operative visit (Week 1): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient.
Post operative visit (Week 2): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient.
Post operative visit (1 months): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient. Topical local anesthetic will be applied on the treated area and the clinical measurements will be taken non-invasively using the pre-fabricated stent, periodontal probe and endo reamer with stopper at one month post surgery.
Post operative visit (6months): Treated site checked for healing and oral hygiene instructions will be reviewed with the patient. Clinical measurements are repeated as described above.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A - PRF plus AFG with a CAF | Experimental | Other: Group A - PRF plus AFG with a CAFGroup A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe. |
| Group B - PRF only with a CAF | Experimental | Other: Group B - PRF only with a CAFGroup B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. |
| Group C - CTG with a CAF | Active comparator | Other: Group C - CTG with a CAFGroup C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Men and women aged 18 years or over
- Miller's Class 1 and Class 2 recession
- Localized gingival recession of 1-6mm present on 1 or 2 continuous single rooted teeth. Gingival recession is measured from the cemental-enamel junction (CEJ; a stable anatomical landmark on every tooth) to the gingival margin.
Key exclusion criteria (5 listed)
- Current tobacco use (greater than 1 cigarette/week) or history of quitting < 5 years previously (self reported)
- Poor oral hygiene (plaque index of 2 or greater) or active periodontal disease (diagnosis of moderate chronic periodontal disease or greater)
- Currently taking aspirin, prescription blood thinners
- Type II diabetes with HbA1c greater than 7
- Immunosuppressed or any other systemic condition that would disqualify subject as an acceptable surgical candidate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group A - PRF plus AFG with a CAFGroup A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots. | Other | Group A - PRF plus AFG with a CAF |
| Group B - PRF only with a CAFGroup B - PRF only with a CAF will be used surgically to cover the exposed roots. | Other | Group B - PRF only with a CAF |
| Group C - CTG with a CAFGroup C - CTG with a CAF will be used surgically to cover the exposed roots. | Other | Group C - CTG with a CAF |
Primary outcome
Evaluate the level of root coverage using PRF plus AFG with a coronally advanced flap or PRF only with a CAF compared to subepithelial connective tissue graft with a CAF for Class 1 and 2 gingival recession defects.
Time frame: Baseline to 6 months
To evaluate the level of root coverage using PRF plus AFG compared to CTG or PRF only compared to CTG
1 secondary outcome
Evaluate the level of keratinized tissue thickness and width using PRF plus AFG with a CAF, PRF only with a CAF or a SCTG with CAF for Class 1 and 2 gingival recession defects.
Time frame: Baseline to 6 months
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2019.
- Background: PubMed 28283682Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients' own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018 Feb;44(1):87-95. doi: 10.1007/s00068-017-0767-9. Epub 2017 Mar 10.
- Results publication: PubMed 28551729Miron RJ, Zucchelli G, Pikos MA, Salama M, Lee S, Guillemette V, Fujioka-Kobayashi M, Bishara M, Zhang Y, Wang HL, Chandad F, Nacopoulos C, Simonpieri A, Aalam AA, Felice P, Sammartino G, Ghanaati S, Hernandez MA, Choukroun J. Use of platelet-rich fibrin in regenerative dentistry: a systematic review. Clin Oral Investig. 2017 Jul;21(6):1913-1927. doi: 10.1007/s00784-017-2133-z. Epub 2017 May 27.
- Results publication: PubMed 19089687Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009 Feb;27(1):63-9. doi: 10.1080/08977190802636713.
- Results publication: PubMed 21740377Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barbe G, Del Corso M, Inchingolo F, Sammartino G. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012 Jun;13(7):1145-52. doi: 10.2174/138920112800624382.
- Results publication: PubMed 28196169Oncu E. The Use of Platelet-Rich Fibrin Versus Subepithelial Connective Tissue Graft in Treatment of Multiple Gingival Recessions: A Randomized Clinical Trial. Int J Periodontics Restorative Dent. 2017 Mar/Apr;37(2):265-271. doi: 10.11607/prd.2741.
- Results publication: PubMed 16504850Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e45-50. doi: 10.1016/j.tripleo.2005.07.009. Epub 2006 Jan 10.
- Results publication: PubMed 16504851Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e51-5. doi: 10.1016/j.tripleo.2005.07.010.
- Results publication: PubMed 16504849Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e37-44. doi: 10.1016/j.tripleo.2005.07.008. Epub 2006 Jan 19.
- Results publication: PubMed 16504852Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):e56-60. doi: 10.1016/j.tripleo.2005.07.011.
- Results publication: PubMed 16504861Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Mar;101(3):299-303. doi: 10.1016/j.tripleo.2005.07.012.
- Individual participant dataSharing planned: Undecided
Related trials for Gingival Recession
Not yet recruiting
Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)
Gingival Recession Localized Moderate, Dental Implant
Recruiting
i-PRF-Based Bioactive Matrix vs. Connective Tissue Graft in the Treatment of Gingival Recessions
Gingival Graft, Recession, Gingival
Recruiting
Palatal Wound Healing After Free Gingival Graft Harvest in Diabetic Patients: A Clinical Trial
Diabetes Mellitus, Gingival Recession, Generalized
Not yet recruiting
Evaluation of the Effect of Smoking on Palatal Donor Site Tissue Profile in the Success of Connective Tissue Grafts
Soft Tissue Augmentation, Gingival Recession Localized Moderate
Active, not recruiting
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival Recession
Gingival Recession
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yogalakshmi Rajendran, BDS MS principal investigator
UCSF School of Dentistry
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group A - PRF plus AFG with a CAF, Group B - PRF only with a CAF and Group C - CTG with a CAF in people with Gingival Recession, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 8 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the level of root coverage using PRF plus AFG with a coronally advanced flap or PRF only with a CAF compared to subepithelial connective tissue graft with a CAF for Class 1 and 2 gingival recession defects. (time frame: Baseline to 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03734458, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2019.